BiDil therapeutic equivalence
FDA issues a letter May 4 confirming that it "has not approved any drug that is therapeutically equivalent or substitutable to" NitroMed's heart failure therapy BiDil. NitroMed filed a Citizen Petition seeking such confirmation from FDA in an effort to quell reports of the availability of generic versions of the isosorbide dinitrate/hydralazine hyrdrochloride combo product. Both components are generically available...
You may also be interested in...
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Use of per- and polyfluoroalkyl substances in cosmetic products appears to be declining, based on voluntary industry registrations with the US Food and Drug Administration. In any event, NGOs are gunning for PFAS' elimination, and the FDA says available data have yet to give a complete safety picture for PFAS used intentionally in cosmetics or present as impurities.